HansBiomed Corporation (KOSDAQ:042520)
South Korea · Delayed Price · Currency is KRW 18,110
-470 (-2.53%)
At close: Oct 22, 2026
HansBiomed Ratios and Metrics
Market cap in millions KRW. Fiscal year is October - September.
Millions KRW. Fiscal year is Oct - Sep.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 258,273 | 235,973 | 127,792 | 207,570 | 92,964 | 160,691 | |
Market Cap Growth | -14.65% | 84.65% | -38.43% | 123.28% | -42.15% | -29.01% |
Enterprise Value | 280,411 | 268,360 | 153,787 | 241,607 | 132,643 | 187,080 |
Last Close Price | 18110.00 | 18170.00 | 9840.00 | 17930.00 | 9610.00 | 16050.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
PE Ratio | - | - | - | - | 15.12 | - |
Forward PE | 11.54 | 13.87 | 13.87 | 13.87 | 6.95 | 6.95 |
PS Ratio | 2.07 | 2.63 | 1.58 | 2.66 | 1.25 | 2.72 |
PB Ratio | 3.31 | 6.96 | 1.90 | 4.16 | 1.96 | 3.38 |
P/TBV Ratio | 3.31 | 7.11 | 1.93 | 4.29 | 2.08 | 3.70 |
P/OCF Ratio | - | 741.27 | 72.67 | - | - | - |
PEG Ratio | - | 1.08 | 1.08 | 1.08 | 1.08 | 1.08 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
EV/Sales Ratio | 2.25 | 2.99 | 1.90 | 3.10 | 1.78 | 3.17 |
EV/EBITDA Ratio | - | - | 25.58 | 231.57 | 21.54 | - |
EV/EBIT Ratio | - | - | 245.82 | - | 105.60 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Debt / Equity Ratio | 0.54 | 1.28 | 0.54 | 0.82 | 1.18 | 1.08 |
Debt / EBITDA Ratio | - | - | 6.06 | 39.43 | 9.08 | - |
Net Debt / Equity Ratio | 0.29 | 1.04 | 0.44 | 0.68 | 0.89 | 0.66 |
Net Debt / EBITDA Ratio | -1.63 | -1.54 | 4.85 | 32.68 | 6.88 | -2.09 |
Net Debt / FCF Ratio | -1.22 | -22.77 | -34.90 | -6.01 | -5.13 | -1.60 |
Asset Turnover | 0.89 | 0.72 | 0.67 | 0.61 | 0.57 | 0.45 |
Inventory Turnover | 1.75 | 1.34 | 1.05 | 1.20 | 1.26 | 1.64 |
Quick Ratio | 0.33 | 0.31 | 0.38 | 0.31 | 0.32 | 0.49 |
Current Ratio | 1.31 | 0.69 | 0.99 | 0.77 | 0.73 | 0.84 |
Return on Equity (ROE) | -29.22% | -63.51% | -13.33% | -49.47% | 10.36% | -37.86% |
Return on Assets (ROA) | -8.15% | -14.05% | 0.32% | -2.04% | 0.60% | -9.46% |
Return on Invested Capital (ROIC) | -18.47% | -33.74% | 0.69% | -4.78% | 1.49% | -25.01% |
Return on Capital Employed (ROCE) | -20.60% | -61.50% | 0.90% | -7.30% | 2.20% | -28.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 21, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Earnings Yield | -7.91% | -13.28% | -5.65% | -11.10% | 6.61% | -11.38% |
FCF Yield | -7.13% | -0.65% | -0.65% | -2.73% | -8.88% | -12.16% |
Buyback Yield / Dilution | -5.73% | -0.29% | -20.83% | 18.41% | -31.21% | -1.48% |
Total Shareholder Return | -5.73% | -0.29% | -20.83% | 18.41% | -31.21% | -1.48% |